Ensysce Biosciences

company

About

Ensysce Biosciences develops an abuse-deterrent and overdose technology that can be applied to 75% of all marketed drugs.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$1.50M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the company is in the process of developing a new class of tamper-proof opioids that prevent both drug abuse and overdoses.

Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$2.50M
Ensysce Biosciences has raised a total of $2.50M in funding over 2 rounds. Their latest funding was raised on Jun 6, 2012 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 6, 2012 Series Unknown $1M 1 Texas Wide Open for Business Detail
Jun 10, 2010 Series A $1.50M 1 Texas Wide Open for Business Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Ensysce Biosciences is funded by 1 investors. Texas Wide Open for Business are the most recent investors.
Investor Name Lead Investor Funding Round
Texas Wide Open for Business Yes Series Unknown